Kornimate/medical-research-clean huggingface dataset:
to study the effects of cd25 and low dose cyclosporin in the treatment of active psoriasis vulgaris

Conditions: Psoriasis

Summary: this study compares the efficacy and analyzes the cellular effects of anti-tac (daclizumab) and cyclosporine in the treatment of psoriasis vulgaris. this is a three-armed study-daclizumab alone, cyclosporine alone, and the combination of both daclizumab and cyclosporine.

the purpose is to study the safety and effectiveness of a new drug called "anti-tac" (anti-cd25) monoclonal antibody used together with low dose cyclosporine in the treatment of psoriasis. while the exact cause of psoriasis is unknown, it is believed to involve white blood cells called lymphocytes, which become activated in the skin. it is believed that these activated cells are responsible for the changes you see as the rash of psoriasis. anti-tac (anti-cd25) monoclonal antibody is designed to block the activation of these lymphocytes. because the anti-tac (anti-cd25) monoclonal antibody targets the specific cells involved in the symptoms of psoriasis, this new drug may be a better way to treat psoriasis. the second drug, cyclosporine, is an fda-approved drug in the treatment of psoriasis. there is evidence in the laboratory that cyclosporine and anti-tac, used together, will have an additive effect. an additional benefit of this study is that we are using a lower dose of cyclosporine than is usually given when it is used alone because it is being used together with anti-tac. this should reduce the side effects usually seen with higher doses of cyclosporine when it is used as a single drug for psoriasis. the purpose of this study is to test the safety and effectiveness of anti-tac (monoclonal antibody and low dose cyclosporine in patients with active, moderate to severe psoriasis vulgaris. we also hope to gain more information on how anti-tac works in the body

Eligibility criteria:
inclusion criteria 1. male or female patients with chronic psoriasis vulgaris (disease stable or worsening for \> 6 months). patients age 16 - 21 will be considered on a case by case basis. patients below 18 will need parental consent. 2. extensive skin involvement. 3. scale, thickness, and erythema in individual psoriasis lesions of at least intensity. 4. psoriasis treated with emollients only for 2 weeks prior to treatment 5. patients with active psoriatic arthritis, if accompanied by psoriasis vulgaris involving more than 5% of the body surface. 6. history of psoriasis that cannot be treated with topical agents or with previous systemic/ photo(chemo)therapy agents. exclusion criteria: 1. . positive serology for hiv, hepatitis b, or hepatitis c. 2. . positive β-hcg titer. for women of childbearing potential, unwillingness or inability to use a contraceptive device during this study if negative for β-hcg. 3. guttate psoriasis, pustular psoriasis, or whole body erythroderma. 4. active infection or persistent fever of unknown origin. 5.) major concurrent illness, which could worsen following treatment with daclizumabtm. 6) any history of an un-treated neoplasm

Keywords: psoriasis daclizumab cyclosporin anti-tac dermatology skin
patient-derived-organoid (pdo) guided versus conventional therapy for advanced inoperable abdominal tumors

Conditions: Organoids

Summary: recent studies that ex vivo drug responses on pdo models across different solid tumours can predict treatment responses to chemotherapeutic agents. in patients with metastatic or inoperable solid abdominal tumours, we perform a pdo based drug screen and to identify drugs that will confer clinical response and compared to conventional treatments

precision oncology aims to improve the clinical outcomes of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumours. however, current challenges in cancer treatment have hampered the broad clinical utility of the gene-drug associations in the clinic. this is particularly valid when it comes to offering alternative treatment options for advanced inoperable patients with chemo-refractory diseases. there is currently no reliable biomarker to predict treatment response. patient-derived organoids (pdos) closely resemble both pheno- and genotypically to patients' tumours. in observational studies, anticancer drug screening ex vivo on pdos has been shown to predict clinical response with high sensitivity and specificity. pdo-based drug screen represents a truly personalised platform by predicting patient-specific drug response with high accuracy. recent technical advancements in growing these pdo 'avatars' from biopsies have made it possible to find anticancer drug options in tumours from advanced inoperable patients, and explore new possibilities for treatment options that otherwise would be missed by standard conventional therapies. pdo-based drug assays permit examination of combinatorial drug testing ex vivo and potentially offer patients treatment options. the clinical utility of treatment based on pdo informed drug options however has not been established. we hypothesize that treatment guided by pdo-based drug screens, when compared to conventional treatment, can lead to better treatment response and clinical outcomes. we propose a phase 2 proof-of-concept randomized controlled trial in patients with inoperable or metastatic abdominal tumours refractory to at least one chemotherapeutic agent. our primary endpoint to this randomised trial is progression-free survival (pfs) at 12 months. in this trial, we in addition expand our current bio-resource of pdos, and further valid pdo guided treatment model by comparing ex vivo pdo drug response to patients' clinical response.

Eligibility criteria:
inclusion criteria: * patients should be older than 18 years, able to provide written consents to trial participation, with eastern cooperative oncology group performance status of 0 or 1, with measurable disease in accordance with response evaluation criteria in solid tumours (recist) version 11. \[ 10 \] with a neutrophil count, hemoglobin \> 9g/dl, serum creatinine \ 50% of normal. the disease is accessible for a biopsy (radiologic or endoscopic) or resection of a metastatic site. exclusion criteria: * unable to give consent, could not obtain a biopsy

Keywords: organoids
efficacy and safety of mexartan potassium tablets (azl-m) and calcium channel blockers (ccb) in the treatment of adults with essential hypertension in chinese population: a national multicenter, prospective, observational study

Conditions: Essential Hypertension

Summary: this is a national multicenter, prospective, observational study. it is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment plans given by doctors: azl-m monotherapy group, ccb monotherapy group (amlodipine besylate tablets or nifedipine controlled-release tablets) and azl-m+ccb (amlodipine besylate tablets or nifedipine controlled-release tablets) combined treatment group. subjects were visited 4 times at baseline, 1 month, 3 months, and 6 months, and the following key indicators of subjects were measured according to the doctor's decision, and the measurement results were collected


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old (one year old); 2. patients diagnosed with essential hypertension; 3. did not receive any antihypertensive drug treatment for at least 3 months before enrollment; 4. eligible to use 80 mg once-daily azl-m at baseline or ccb (amlodipine besylate tablets or nifedipine controlled-release tablets) or ccb (besylate amlodipine tablets or nifedipine controlled-release tablets) + azl-m 80 mg once-daily combination therapy; volunteer to participate in this study, understand and sign the written informed consent. exclusion criteria: 1. used antihypertensive drugs for indications other than hypertension within 3 months before enrollment; 2. has a history of alcoholism, drug abuse or illegal drug use; 3. pregnant, breastfeeding women, and those who plan to become pregnant in the near future; 4. life expectancy is less than one year; participating in other clinical trials.

Keywords: essential hypertension
continuation of anti-osteoporotic treatment 1 year after initial administration

Conditions: Osteoporosis Fracture

Summary: the aim of this observational study is to assess the obstacles and levers to the continuation of anti-osteoporotic treatment, and to identify those where action could be taken to improve the quality of care for fractured patients. the individual and collective stakes are high. fracture is the most feared complication of osteoporosis. the current under-diagnosis and under-treatment of this chronic pathology exposes patients to a high risk of early re-fracture, with the associated morbidity and mortality. general practitioners have a major role to play in monitoring and coordinating patients' healthcare pathways. the aim of this study is to assess ways of improving osteoporosis management in order to improve quality of life and disability-free life expectancy for individual patients. the public health and economic stakes are equally high. it is by identifying the obstacles that prospective work on the key elements to be implemented could help optimize osteoporosis management.

selection of patients hospitalized at the rocheplane medical center between june 2021 and may 2022, following a severe osteoporotic fracture and having received a first dose of antiosteoporotic treatment during their overall stay (initial admission department + cmr). sending of an information letter and request for non-objection from patients or their trusted support person, with a 1-month cooling-off period to express opposition. collection of variables of interest from cmr patients' medical records, followed by administration of a telephone hetero-questionnaire (transferred to excel) to patients or their families 1 year after fracture occurrence. if the patient or family did not answer the questionnaire, or if it was incomplete (missing data), the information could be sought by telephone from the attending physician.

Eligibility criteria:
inclusion criteria: * hospitalization in cmr's geriatric rehabilitation department between 01/06/2021 and 31/05/2022 * age: 75 and over * admitted with severe post-fracture osteoporosis * having received a first dose of antiosteoporotic treatment between the day the fracture occurred and discharge from cmr (either in an inpatient unit prior to cmr, or at cmr) exclusion criteria: * having objected to the use of his/her data for research purposes * subject under guardianship or deprived of liberty. * pathological fracture * anti-osteoporotic treatment prior to fracture * 1-year follow-up made impossible by lack of contact with patient, family or attending physician.

Keywords: antiosteoporotic treatment professional practice assessment
chemotherapy with or without imatinib and/or peripheral stem cell transplant in acute lymphoblastic leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. a peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. when the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. giving combination chemotherapy together with imatinib mesylate and peripheral stem cell transplant may be an effective treatment for acute lymphoblastic leukemia. nevertheless, in the last few years gimema has pubblished a paper in which 100% of ph+ all patients reach hcr only with imatinib, without any chemiotherapy. thus, this treatment will be implemented in patients pertaining to this category.


Eligibility criteria:
disease characteristics: * diagnosis of acute lymphoblastic leukemia (all) meeting the following criteria: * negative myeloperoxidase stain * phenotype t (t-all) or b (b-all) * no mature b-all (fab l3, serum immunoglobulin-positive, terminal deoxynucleotidyl transferase-negative) patient characteristics: * creatinine ≤ 2.5 mg/dl (after adequate hydration) * sgot and sgpt ≤ 3 times upper limit of normal * lvef ≥ 50% * no severe psychiatric disorders * no other concurrent malignant disease * no presence of documented infections not responding to antibiotic and/or antifungal therapy * not pregnant prior concurrent therapy: * no prior steroids * no prior antiblastic chemotherapy * no other concurrent chemotherapy or radiotherapy

Keywords: b-cell adult acute lymphoblastic leukemia t-cell adult acute lymphoblastic leukemia untreated adult acute lymphoblastic leukemia l1 adult acute lymphoblastic leukemia l2 adult acute lymphoblastic leukemia tdt positive adult acute lymphoblastic leukemia
preventing covid-19 complications with low- and high-dose anticoagulation

Conditions: COVID; Sars-CoV2

Summary: the ongoing covid-19 pandemic affects millions of humans worldwide and has led to thousands of acute medical hospitalizations. there is evidence that hospitalized cases often suffer from an important infection-related coagulopathy and from elevated risks of thrombosis. anticoagulants may have positive effects here, to reduce the burden of thrombotic disease and the hyperactivity of coagulation, and may also hold beneficial anti-inflammatory effects against sepsis and the development of ards. the investigators hypothesize that high-dose anticoagulants, compared with low-dose anticoagulants, lower the risk of venous and arterial thrombosis, disseminated intravascular coagulation (dic) and mortality. this open-label controlled trial will randomize hospitalized adults with severe covid-19 infection to therapeutic anticoagulation vs. thromboprophylaxis during the hospital stay.


Eligibility criteria:
inclusion criteria: adult patient with covid-19 infections, admitted to: * an acute non-critical medical ward with admission d-dimer levels \>1,000ng/ml, or * an acute critical ward (icu, intermediate care unit) exclusion criteria: * ongoing or planned therapeutic anticoagulation for any other indication * contra-indication to therapeutic anticoagulation * hypersensitivity to heparin * personal history of heparin-induced thrombocytopenia * suspected or confirmed bacterial endocarditis * bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder * organic lesion prone to bleeding * platelet count \<50g/l, hb level \<80g/l * ongoing or recent (\<30 days) major bleeding, ischemic stroke, trauma, surgery * use of dual antiplatelet therapy * pregnancy * bodyweight \ 150kg. * end of life care setting * unwillingness to consent * ongoing participation in a covid-19 randomized clinical trial testing another therapeutic intervention

Keywords: anticoagulation heparin thrombosis
aripiprazole in anorexia nervosa

Conditions: Anorexia Nervosa

Summary: evidence is lacking on the effects of different psychotropic drugs in the treatment of anorexia nervosa (ar). however, hva levels seem to be elevated in this disease, therefore suggesting a role for drugs with a partial agonist profile on dopaminergic receptors. this is a pilot study assessing the effects of aripiprazole in teenagers with ar, compared with a placebo.


Eligibility criteria:
inclusion criteria: * age between 12 and 18 * diagnostic criteria for anorexia nervosa (dsm-iv-tr (includes bmi below 17.5kg/m2 and above 14 kg/m2) confirmed by a psychiatrist and validated by k-sads-pl interview * severity criteria requiring hospital admission * consent given by parents and patients exclusion criteria: * psychotic illness * antipsychotic therapy at inclusion * pregnancy and breastfeeding * antipsychotic drug allergy * prior head trauma, malignant neuroleptic syndrome or epilepsy * relevant comorbidities requiring therapy * detection of abuse drugs in urine test * treatment with neuroleptic, antidepressant or mood stabilizers during 2 weeks prior to randomization (4 weeks in case of fluoxetine) * suicidal or homicidal thoughts * iq below 70
evaluation of the effects of home-based functional exercise on patients with acl

Conditions: Anterior Cruciate Ligament Rupture; Rehabilitation

Summary: this study will evaluate the effect of home-based functional exercise on patients with anterior cruciate ligament rupture reconstruction based on the health belief model. about 360 participants will be randomly allocated into two groups. one group will randomized to receive precautions and rehabilitation progress reminders and other news by optimized wechat applet regularly, while the other group will randomized to receive the rehabilitation exercise guidance during routine discharge.

with the development of national fitness and sports, the incidence of anterior cruciate ligament (acl) injuries has increased. acl reconstruction is the best treatment for acl injury. the success rate of surgery is high, but the patient still needs to rehabilitate after surgery, otherwise it is difficult to fully recover knee function. however, the rehabilitation medical resources in china are obviously insufficient. patients who have undergone acl reconstruction usually return home to work according to the rehabilitation plan. however, the adherence is still poor, and it is difficult to achieve the expected effect. the wechat public account and its affiliated applets have been widely used in different health fields. the health belief model (hbm) is a guiding theory commonly used in health education to guide patients for behavioral changes. this study aims to use the wechat small program to explore the effects of optimized the existing peking university third hospital sports medicine wechat small program by using hbm to improve the adherence of patients with home-based functional exercise after acl injury reconstruction.

Eligibility criteria:
inclusion criteria: * (1)age between 18 and 45； * (2)the first time to do simple acl reconstruction, may be combined with cartilage -dressing and partial meniscectomy, patients with consistent postoperative rehabilitation plans; * (3)having the ability of basic literacy, communication and accessibility; * (4)having a smartphone, using wechat or can learn to use wechat. exclusion criteria: * (1)having history of joint infection, joint tuberculosis or osteomyelitis, or surgery in the lower extremities within 6 months; * (2)being combined with severe heart, brain, kidney and other organ dysfunction; * (3)having other serious knee injuries; * (4)being with mental illness or cognitive impairment, unable to learn and participate in rehabilitation training; * (5)having participated in other similar rehabilitation function training programs, or transferred to other medical institutions after discharge; * (6)doing not disagree to participate in the study,and not sign the informed consent.

Keywords: functional exercise health belief model
investigation of palpation pressure sensitivity

Conditions: Sensitivity Training Groups

Summary: the study is planned for searching physiotherapists palpation abilities. there were 2 groups of physiotherapists. they were asked for to push target pressures. after making some exercise, the assesment was done again.

2 groups of physiotherapists with different fields of experience were attended to study. fingers are positioned on the marked area at the center point of the scale. therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. in each measurements, the value on the scale was recorded without being shown to the participants. after the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. participants were given a total of 10 minutes for the trials. then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain that pressure for 5 seconds. the weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.

Eligibility criteria:
inclusion criteria: * willing to participate, * active working patients as a physiotherapists pediatric, neurologic, orthopedic physiotherapy, manual therapy or osteopathy. exclusion criteria: * having a neurological disease (multiple sclerosis, polyneuropathy, etc.) -having a disease that may cause neurological deficit in the upper extremity (cervical myelopathy, carpal tunnel syndrome, pronator teres syndrome, cubital tunnel syndrome, --- * guyon canal syndrome) * refuse to participate

Keywords: palpation manual therapy pressure
durability extension study to assess clinical activity and safety of enobosarm (gtx-024) in stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the study will enroll only from the first 225 subjects who were randomly assigned to treatment in g201002 (irrespective of the treatment allocation, i.e., gtx-024 or placebo) and who have completed the 12-week treatment period and 16-week durability period to assess the long-term durability of response to gtx-024 on sui symptoms. the extension study will follow subjects for an additional 20 weeks to help better assess the durability of response in these subjects and will provide additional efficacy and safety data for the subjects. subjects will not be provided with any study treatments and will be off-drug during this extension study.


Eligibility criteria:
inclusion criteria: * be one of the first 225 subjects who were randomly assigned to treatment in g201002 (phase 2 study) and have completed the 12-week treatment and 16-week durability periods * be able to read, understand, and provide written, dated informed consent prior to enrollment in the current study (within 2 weeks of completing g201002) and be likely to comply with the study protocol and communicate with study personnel about aes and other clinically important information * agree to maintain a stable dose of any medication known to affect lower urinary tract function, including but not limited to anticholinergics, tricyclic antidepressants, beta-3 adrenergic agonists, or α-adrenergic blockers, throughout the duration of the study exclusion criteria: * starts any new treatment (medication, pelvic floor physical therapy, or other treatment known to impact the pelvic floor) after completing g201002 that is known or suspected to affect lower urinary tract function, including vaginal rejuvenation * has a current or past history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with interpretation of study results
opting for breast reconstruction after mastectomy or not: search for influencing factors

Conditions: Breast Cancer Female; Mastectomy; Breast Reconstruction

Summary: the purpose of this study is to investigate the factors influencing the decision about breast reconstruction after breast amputation for breast cancer. the study will be conducted at the university hospital in brussels using only a questionnaire. the results might help us to evaluate and improve the satisfaction among patients about the received information and guidance.

the questionnaire will be completed during one interview. this interview will take place preferably right after the patient visited her doctor at the breast clinic at the university hospital in brussels. before starting the interview all the necessary information to decide whether or not to participate in the study will be given as well as the time to read the informed consent carefully.

Eligibility criteria:
inclusion criteria: * female * dutch speaking * must have undergone a mastectomy for breast cancer in the following period: 2010 - 2015 * must be a patient of the breast clinic at the university hospital in brussels exclusion criteria: * bilateral preventive mastectomy (and therefore no history of breast cancer in any of the breasts)

Keywords: breast cancer female mastectomy breast reconstruction questionnaire